Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the nationwide survey of primary liver cancer in Japan

K. Nouso, K. Miyahara, D. Uchida, K. Kuwaki, N. Izumi, M. Omata, T. Ichida, M. Kudo, Y. Ku, N. Kokudo, Michiie Sakamoto, O. Nakashima, T. Takayama, O. Matsui, Y. Matsuyama, K. Yamamoto

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Background:The efficacy of hepatic arterial infusion chemotherapy for the treatment of advanced hepatocellular carcinoma (HCC) remains unclear.Methods:The outcome of 476 patients with HCC who underwent hepatic arterial infusion chemotherapy with 5-fluorouracil and cisplatin (HAIC) were compared with 1466 patients who did not receive active therapy.Results:A survival benefit of the therapy after adjusting for known risk factors was observed (hazard ratio, 0.48; 95% CI, 0.41-0.56; P<0.0001). In propensity score-matched analysis (n=682), median survival time was longer for patients who underwent chemotherapy (14.0 months) than for patients who did not receive active treatment (5.2 months, P<0.0001).Conclusion:For advanced HCC, HAIC is considered to be an effective treatment.

Original languageEnglish
Pages (from-to)1904-1907
Number of pages4
JournalBritish Journal of Cancer
Volume109
Issue number7
DOIs
Publication statusPublished - 2013 Oct 1

Fingerprint

Liver Neoplasms
Fluorouracil
Cisplatin
Hepatocellular Carcinoma
Japan
Drug Therapy
Liver
Therapeutics
Propensity Score
Survival
Surveys and Questionnaires

Keywords

  • 5-fluorouracil
  • chemotherapy
  • cisplatin
  • hepatocellular carcinoma
  • liver neoplasm
  • propensity score

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the nationwide survey of primary liver cancer in Japan. / Nouso, K.; Miyahara, K.; Uchida, D.; Kuwaki, K.; Izumi, N.; Omata, M.; Ichida, T.; Kudo, M.; Ku, Y.; Kokudo, N.; Sakamoto, Michiie; Nakashima, O.; Takayama, T.; Matsui, O.; Matsuyama, Y.; Yamamoto, K.

In: British Journal of Cancer, Vol. 109, No. 7, 01.10.2013, p. 1904-1907.

Research output: Contribution to journalArticle

Nouso, K, Miyahara, K, Uchida, D, Kuwaki, K, Izumi, N, Omata, M, Ichida, T, Kudo, M, Ku, Y, Kokudo, N, Sakamoto, M, Nakashima, O, Takayama, T, Matsui, O, Matsuyama, Y & Yamamoto, K 2013, 'Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the nationwide survey of primary liver cancer in Japan', British Journal of Cancer, vol. 109, no. 7, pp. 1904-1907. https://doi.org/10.1038/bjc.2013.542
Nouso, K. ; Miyahara, K. ; Uchida, D. ; Kuwaki, K. ; Izumi, N. ; Omata, M. ; Ichida, T. ; Kudo, M. ; Ku, Y. ; Kokudo, N. ; Sakamoto, Michiie ; Nakashima, O. ; Takayama, T. ; Matsui, O. ; Matsuyama, Y. ; Yamamoto, K. / Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the nationwide survey of primary liver cancer in Japan. In: British Journal of Cancer. 2013 ; Vol. 109, No. 7. pp. 1904-1907.
@article{11abbf1501624cd9b745094add0e3e5d,
title = "Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the nationwide survey of primary liver cancer in Japan",
abstract = "Background:The efficacy of hepatic arterial infusion chemotherapy for the treatment of advanced hepatocellular carcinoma (HCC) remains unclear.Methods:The outcome of 476 patients with HCC who underwent hepatic arterial infusion chemotherapy with 5-fluorouracil and cisplatin (HAIC) were compared with 1466 patients who did not receive active therapy.Results:A survival benefit of the therapy after adjusting for known risk factors was observed (hazard ratio, 0.48; 95{\%} CI, 0.41-0.56; P<0.0001). In propensity score-matched analysis (n=682), median survival time was longer for patients who underwent chemotherapy (14.0 months) than for patients who did not receive active treatment (5.2 months, P<0.0001).Conclusion:For advanced HCC, HAIC is considered to be an effective treatment.",
keywords = "5-fluorouracil, chemotherapy, cisplatin, hepatocellular carcinoma, liver neoplasm, propensity score",
author = "K. Nouso and K. Miyahara and D. Uchida and K. Kuwaki and N. Izumi and M. Omata and T. Ichida and M. Kudo and Y. Ku and N. Kokudo and Michiie Sakamoto and O. Nakashima and T. Takayama and O. Matsui and Y. Matsuyama and K. Yamamoto",
year = "2013",
month = "10",
day = "1",
doi = "10.1038/bjc.2013.542",
language = "English",
volume = "109",
pages = "1904--1907",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the nationwide survey of primary liver cancer in Japan

AU - Nouso, K.

AU - Miyahara, K.

AU - Uchida, D.

AU - Kuwaki, K.

AU - Izumi, N.

AU - Omata, M.

AU - Ichida, T.

AU - Kudo, M.

AU - Ku, Y.

AU - Kokudo, N.

AU - Sakamoto, Michiie

AU - Nakashima, O.

AU - Takayama, T.

AU - Matsui, O.

AU - Matsuyama, Y.

AU - Yamamoto, K.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Background:The efficacy of hepatic arterial infusion chemotherapy for the treatment of advanced hepatocellular carcinoma (HCC) remains unclear.Methods:The outcome of 476 patients with HCC who underwent hepatic arterial infusion chemotherapy with 5-fluorouracil and cisplatin (HAIC) were compared with 1466 patients who did not receive active therapy.Results:A survival benefit of the therapy after adjusting for known risk factors was observed (hazard ratio, 0.48; 95% CI, 0.41-0.56; P<0.0001). In propensity score-matched analysis (n=682), median survival time was longer for patients who underwent chemotherapy (14.0 months) than for patients who did not receive active treatment (5.2 months, P<0.0001).Conclusion:For advanced HCC, HAIC is considered to be an effective treatment.

AB - Background:The efficacy of hepatic arterial infusion chemotherapy for the treatment of advanced hepatocellular carcinoma (HCC) remains unclear.Methods:The outcome of 476 patients with HCC who underwent hepatic arterial infusion chemotherapy with 5-fluorouracil and cisplatin (HAIC) were compared with 1466 patients who did not receive active therapy.Results:A survival benefit of the therapy after adjusting for known risk factors was observed (hazard ratio, 0.48; 95% CI, 0.41-0.56; P<0.0001). In propensity score-matched analysis (n=682), median survival time was longer for patients who underwent chemotherapy (14.0 months) than for patients who did not receive active treatment (5.2 months, P<0.0001).Conclusion:For advanced HCC, HAIC is considered to be an effective treatment.

KW - 5-fluorouracil

KW - chemotherapy

KW - cisplatin

KW - hepatocellular carcinoma

KW - liver neoplasm

KW - propensity score

UR - http://www.scopus.com/inward/record.url?scp=84885176975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885176975&partnerID=8YFLogxK

U2 - 10.1038/bjc.2013.542

DO - 10.1038/bjc.2013.542

M3 - Article

VL - 109

SP - 1904

EP - 1907

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 7

ER -